Philip He

4.1k total citations · 1 hit paper
22 papers, 459 citations indexed

About

Philip He is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Philip He has authored 22 papers receiving a total of 459 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Surgery. Recurrent topics in Philip He's work include Cancer Immunotherapy and Biomarkers (10 papers), Colorectal Cancer Treatments and Studies (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Philip He is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Colorectal Cancer Treatments and Studies (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Philip He collaborates with scholars based in United States, Spain and Japan. Philip He's co-authors include Alejandra Negro, Ghassan K. Abou‐Alfa, Robin Kate Kelley, Yoon‐Koo Kang, Bruno Sangro, Masatoshi Kudo, Kabir Mody, В. В. Бредер, Lorenza Rimassa and Alexander Vasilyev and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

Philip He

19 papers receiving 456 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.

2022 259 citations Ghassan K. Abou‐Alfa, Masatoshi Kudo et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Philip He United States	7	279	270	106	92	84	22	459
Quanren Wang China	1	245 0.9×	131 0.5×	148 1.4×	82 0.9×	67 0.8×	2	368
Damir Begic Spain	6	359 1.3×	465 1.7×	137 1.3×	154 1.7×	101 1.2×	9	612
Oxana Crysler United States	7	270 1.0×	214 0.8×	62 0.6×	121 1.3×	60 0.7×	25	432
Daniel Almquist United States	8	169 0.6×	102 0.4×	85 0.8×	48 0.5×	24 0.3×	18	303
Claudia Angela Maria Fulgenzi United Kingdom	12	226 0.8×	166 0.6×	85 0.8×	63 0.7×	60 0.7×	47	416
Satheesh Chiradoni Thungappa India	4	174 0.6×	201 0.7×	71 0.7×	65 0.7×	47 0.6×	13	305
Xuqi Sun China	8	115 0.4×	192 0.7×	72 0.7×	47 0.5×	16 0.2×	27	282
Alexander Vasilyev Russia	2	158 0.6×	196 0.7×	74 0.7×	61 0.7×	38 0.5×	3	284
Songqiang Zhou China	9	107 0.4×	178 0.7×	82 0.8×	56 0.6×	13 0.2×	15	294

Countries citing papers authored by Philip He

Since Specialization

Citations

This map shows the geographic impact of Philip He's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip He with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip He more than expected).

Fields of papers citing papers by Philip He

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip He. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip He. The network helps show where Philip He may publish in the future.

Co-authorship network of co-authors of Philip He

This figure shows the co-authorship network connecting the top 25 collaborators of Philip He. A scholar is included among the top collaborators of Philip He based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip He. Philip He is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

He, Philip, Haijun Ma, Revathi Ananthakrishnan, et al.. (2025). Ensuring Quality and Interpretability of Progression Free Survival and Overall Survival in Oncology Clinical Trials. Therapeutic Innovation & Regulatory Science. 59(6). 1495–1505.

He, Philip, Dhiraj Gambhire, Haiming Zhou, et al.. (2025). Correlation between tumor growth rate and survival in patients with metastatic breast cancer treated with trastuzumab deruxtecan. The Oncologist. 30(5).

Liu, Tianyu, et al.. (2025). Pointwise Mutual Information as a Performance Gauge for Retrieval-Augmented Generation. University of Groningen research database (University of Groningen / Centre for Information Technology). 1628–1647.

Lu, Zhaohua, et al.. (2024). A Bayesian Hybrid Design With Borrowing From Historical Study. Pharmaceutical Statistics. 24(2). e2466–e2466. 1 indexed citations

Oh, Do‐Youn, et al.. (2024). Delayed Separation of Kaplan–Meier Curves is Commonly Observed in Studies of Advanced/Metastatic Solid Tumors Treated with Anti-PD-(L)1 Therapy: Systematic Review and Meta-Analysis. Targeted Oncology. 20(1). 45–56. 2 indexed citations

Broglio, Kristine, et al.. (2024). A Systematic Review of Adaptive Seamless Clinical Trials for Late-Phase Oncology Development. Therapeutic Innovation & Regulatory Science. 58(5). 917–929. 1 indexed citations

He, Philip, et al.. (2024). Augmenting external control arms using Bayesian borrowing: a case study in first-line non-small cell lung cancer. Journal of Comparative Effectiveness Research. 13(5). e230175–e230175. 2 indexed citations

Song, Xuyang, Robin Kate Kelley, Anis A. Khan, et al.. (2022). Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma. Clinical Cancer Research. 29(4). 754–763. 21 indexed citations

Wang, Lühua, Ming Chen, Ken Kato, et al.. (2022). A phase 3 randomized, double-blind, placebo-controlled, multicenter, global study of durvalumab with and after chemoradiotherapy in patients with locally advanced, unresectable esophageal squamous cell carcinoma: KUNLUN.. Journal of Clinical Oncology. 40(4_suppl). TPS373–TPS373. 14 indexed citations

10.

Martínez‐Martí, Alex, Margarita Majem, Fabrice Barlési, et al.. (2021). LBA42 COAST: An open-label, randomised, phase II platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC. Annals of Oncology. 32. S1320–S1320. 19 indexed citations

11.

Yu, Chang, Xiang Huang, Hui Nian, & Philip He. (2021). A weighted log‐rank test and associated effect estimator for cancer trials with delayed treatment effect. Pharmaceutical Statistics. 20(3). 528–550. 6 indexed citations

12.

McCoon, Patricia, Young S. Lee, Robin Kate Kelley, et al.. (2021). T-cell receptor pharmacodynamics associated with survival and response to tremelimumab (T) in combination with durvalumab (D) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).. Journal of Clinical Oncology. 39(15_suppl). 4087–4087. 5 indexed citations

13.

Song, Xuyang, Robin Kate Kelley, Anis A. Khan, et al.. (2021). Exposure-response (E-R) efficacy and safety (E-S) analyses of tremelimumab as monotherapy or in combination with durvalumab in patients (pts) with unresectable hepatocellular carcinoma (uHCC).. Journal of Clinical Oncology. 39(3_suppl). 313–313. 2 indexed citations

14.

Kelley, Robin Kate, Bruno Sangro, William Proctor Harris, et al.. (2020). Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).. Journal of Clinical Oncology. 38(15_suppl). 4508–4508. 82 indexed citations

15.

Li, Weimin, Sophie Wildsmith, Jiabu Ye, et al.. (2020). Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: Durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure.. Journal of Clinical Oncology. 38(15_suppl). 6511–6511. 24 indexed citations

16.

Wildsmith, Sophie, Jill Walker, Anne L’Hernault, et al.. (2020). 266 Tumour mutation burden (TMB) and efficacy outcomes in the phase III DANUBE study of advanced urothelial carcinoma (UC). SHILAP Revista de lepidopterología. A163.2–A164. 3 indexed citations

17.

Herbst, Roy S., Fabrice Barlési, L. Paz-Ares, et al.. (2019). P1.04-28 COAST: Durvalumab Alone or with Novel Agents for Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S450–S451. 4 indexed citations

18.

Campelo, Rosario García, Patrick M. Forde, Walter Weder, et al.. (2019). P2.04-28 NeoCOAST: Neoadjuvant Durvalumab Alone or with Novel Agents for Resectable, Early-Stage (I–IIIA) Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S719–S719. 7 indexed citations

19.

Schütte, Wolfgang, Fabrice Barlési, K Park, et al.. (2017). Efficacy, safety and predictive biomarker results from OAK, a randomized phase III study comparing atezolizumab with docetaxel in patients with advanced NSCLC. Pneumologie. 71(S 01). S1–S125. 1 indexed citations

20.

Andtbacka, Robert Hans Ingemar, Howard L. Kaufman, Kevin J. Harrington, et al.. (2016). Timing of onset and resolution of adverse events in patients with unresectable stage IIIB-IVM1a melanoma treated with talimogene laherparepvec (T-VEC) in OPTiM. Melanoma Research. 26. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact